The two groups were different in terms of their incidental stroke, with the SGLT2 inhibitor users exhibiting a substantially high risk of NOS with male, an adjusted HR = 1.34 (95% CI: 1.30 to 1.39) than female. This evidence concerns the gene SLC5A2 and Stroke.